Sarah C. Edwards

Sarah C. Edwards

Auto-generated profile, based on publicly available information

Sarah C. Edwards

Cancer Research UK Beatson Institute, Glasgow, UK 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SESarah C. Edwards
Sarah C. Edwards
AHAnn Hedley
Ann Hedley
WHWilma H.M. Hoevenaar
Wilma H.M. Hoevenaar
RWRobert Wiesheu
Robert Wiesheu
TGTeresa Glauner
Teresa Glauner
SCSeth B. Coffelt
Seth B. Coffelt
IL-17A–producing γδ T cells in mice consist primarily of Vγ6+ tissue-resident cells and Vγ4+ circulating cells. How these γδ T cell subsets are regulated during homeostasis and cancer remains poorly understood. Using single-cell RNA sequencing and flow cytommetry, we show that lung Vγ4+ and Vγ6+ cells from tumor-free and tumor-bearing mice express contrasting cell surface molecules as well as distinct co-inhibitory molecules, which function to suppress their expansion. Vγ6+ cells express constitutively high levels of PD-1, whereas Vγ4+ cells upregulate TIM-3 in response to tumor-derived IL-1β and IL-23. Inhibition of either PD-1 or TIM-3 in mammary tumor–bearing mice increased Vγ6+ and Vγ4+ cell numbers, respectively. We found that genetic deletion of γδ T cells elicits responsiveness to anti–PD-1 and anti–TIM-3 immunotherapy in a mammary tumor model that is refractory to T cell checkpoint inhibitors, indicating that IL-17A–producing γδ T cells instigate resistance to immunotherapy. Together, these data demonstrate how lung IL-17A–producing γδ T cell subsets are differentially controlled by PD-1 and TIM-3 in steady-state and cancer.

27 February 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SESarah C. Edwards
Sarah C. Edwards
CSCaroline E. Sutton
Caroline E. Sutton
KLKristin Ladell
Kristin Ladell
Emma GrantEmma Grant
Emma Grant
JMJames E. McLaren
James E. McLaren
KMKingston Mills
Kingston Mills
T cells are classically recognized as distinct subsets that express αβ or γδ TCRs. We identify a novel population of T cells that coexpress αβ and γδ TCRs in mice and humans. These hybrid αβ-γδ T cells arose in the murine fetal thymus by day 16 of ontogeny, underwent αβ TCR–mediated positive selection into CD4+ or CD8+ thymocytes, and constituted up to 10% of TCRδ+ cells in lymphoid organs. They expressed high levels of IL-1R1 and IL-23R and secreted IFN-γ, IL-17, and GM-CSF in response to canonically restricted peptide antigens or stimulation with IL-1β and IL-23. Hybrid αβ-γδ T cells were transcriptomically distinct from conventional γδ T cells and displayed a hyperinflammatory phenotype enriched for chemokine receptors and homing molecules that facilitate migration to sites of inflammation. These proinflammatory T cells promoted bacterial clearance after infection with Staphylococcus aureus and, by licensing encephalitogenic Th17 cells, played a key role in the development of autoimmune disease in the central nervous system.

27 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSophie Curio
Sophie Curio
SESarah C. Edwards
Sarah C. Edwards
TSToshiyasu Suzuki
Toshiyasu Suzuki
JMJenny McGovern
Jenny McGovern
CTChiara Triulzi
Chiara Triulzi
NGNadia Guerra
Nadia Guerra
γδT cells are unconventional T cells particularly abundant in mucosal tissues that play an important role in tissue surveillance and homeostasis. γδT cell activation is mediated by the T cell receptor composed of γ and δ chains, as well as activating receptors for stress-induced ligands, such as NKG2D. Contrary to the well-established anti-tumor function of γδT cells, recent studies have shown that γδT cells can promote tumor development in certain contexts. However, the mechanisms leading to this diseasepromoting role remain poorly understood. Here, we show that mice lacking γδT cells survive longer in a mouse model of intestinal cancer, further supporting their pro-tumoral role. In a surprising conceptual twist, we found that these pro-tumor γδT cells are regulated by NKG2D signaling, a receptor normally associated with cancer cell killing. Germline deletion of Klrk1 , the gene encoding NKG2D, reduced the frequency of γδT cells in the tumor microenvironment and delayed tumor progression. We further show that blocking NKG2D reduces the capability of γδT cells to produce IL-17A in the pre-metastatic lung and that co-culture of lung T cells with NKG2D ligand-expressing tumor cells specifically increases the frequency of γδT cells. Together, these data support the hypothesis that in a tumor microenvironment where NKG2D ligands are constitutively expressed, γδT cells accumulate in an NKG2D-dependent manner and drive tumor progression by secreting pro-inflammatory cytokines, such as IL-17A.